YU26103A - Kombinacija jednog antagonista cbi receptora i sibutramina, farmaceutski oblici koji ih sadrže i njihova upotreba u lečenju gojaznosti - Google Patents

Kombinacija jednog antagonista cbi receptora i sibutramina, farmaceutski oblici koji ih sadrže i njihova upotreba u lečenju gojaznosti

Info

Publication number
YU26103A
YU26103A YU26103A YUP26103A YU26103A YU 26103 A YU26103 A YU 26103A YU 26103 A YU26103 A YU 26103A YU P26103 A YUP26103 A YU P26103A YU 26103 A YU26103 A YU 26103A
Authority
YU
Yugoslavia
Prior art keywords
sibutramin
association
pharmaceutical compositions
compositions containing
receptor antagonist
Prior art date
Application number
YU26103A
Other languages
English (en)
Inventor
Odile Piot-Grosjean
Philippe Picaut
Francois Petit
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8854974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU26103(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of YU26103A publication Critical patent/YU26103A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na kombinaciju jednog antagoniste CB1 receptora i sibutramina, farmaceutske oblike koji ih sadrže i njihovu upotrebu u lečenju gojaznosti.[The invention concerns the association of the CB1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity.
YU26103A 2000-10-04 2001-10-01 Kombinacija jednog antagonista cbi receptora i sibutramina, farmaceutski oblici koji ih sadrže i njihova upotreba u lečenju gojaznosti YU26103A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0012646A FR2814678B1 (fr) 2000-10-04 2000-10-04 Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite

Publications (1)

Publication Number Publication Date
YU26103A true YU26103A (sh) 2006-08-17

Family

ID=8854974

Family Applications (1)

Application Number Title Priority Date Filing Date
YU26103A YU26103A (sh) 2000-10-04 2001-10-01 Kombinacija jednog antagonista cbi receptora i sibutramina, farmaceutski oblici koji ih sadrže i njihova upotreba u lečenju gojaznosti

Country Status (29)

Country Link
EP (1) EP1328269B2 (sh)
JP (1) JP4221221B2 (sh)
KR (1) KR20030036885A (sh)
CN (1) CN100409845C (sh)
AT (1) ATE267595T1 (sh)
AU (2) AU2001293936B2 (sh)
BG (1) BG107739A (sh)
BR (1) BR0114410A (sh)
CA (1) CA2424934A1 (sh)
DE (1) DE60103556T3 (sh)
DK (1) DK1328269T5 (sh)
EA (1) EA005924B1 (sh)
EE (1) EE200300121A (sh)
ES (1) ES2217191T5 (sh)
FR (1) FR2814678B1 (sh)
HR (1) HRP20030249A2 (sh)
HU (1) HUP0302044A3 (sh)
IL (1) IL155236A0 (sh)
MX (1) MXPA03002845A (sh)
NO (1) NO20031521L (sh)
NZ (1) NZ524904A (sh)
PL (1) PL362833A1 (sh)
PT (1) PT1328269E (sh)
SI (1) SI1328269T2 (sh)
SK (1) SK4032003A3 (sh)
TR (1) TR200401264T4 (sh)
WO (1) WO2002028346A2 (sh)
YU (1) YU26103A (sh)
ZA (1) ZA200303015B (sh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
AU2003223510B2 (en) 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
EP1583742B1 (en) 2003-01-02 2009-12-02 F. Hoffmann-La Roche Ag Cb 1 receptour inverse agonists
DE60322114D1 (de) 2003-01-02 2008-08-21 Hoffmann La Roche Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
NZ543451A (en) 2003-06-11 2008-08-29 Merck & Co Inc Substituted 3-alkyl and 3-alkenyl azetidine derivitives
RU2344132C2 (ru) 2003-06-20 2009-01-20 Ф.Хоффманн-Ля Рош Аг 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
CA2537535A1 (en) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Novel medical use of selective cb1-receptor antagonists
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
WO2005049615A1 (en) * 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
BRPI0417376A (pt) 2003-12-08 2007-04-10 Hoffmann La Roche compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
KR100843023B1 (ko) 2004-01-28 2008-07-01 에프. 호프만-라 로슈 아게 스피로-5환 화합물
EP1749002B1 (en) 2004-05-10 2009-05-27 F.Hoffmann-La Roche Ag Pyrrole or imidazole amides for treating obesity
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
FR2876689B1 (fr) * 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
RU2394027C2 (ru) 2004-10-27 2010-07-10 Ф. Хоффманн-Ля Рош Аг Новые индольные или бензимидазольные производные
WO2006050842A1 (en) 2004-11-09 2006-05-18 F. Hoffmann-La Roche Ag Dibenzosuberone derivatives
RU2404164C2 (ru) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2007102999A2 (en) * 2006-02-21 2007-09-13 Ampla Pharmaceuticals Inc. Cb1 antagonists and inverse agonists
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
KR20090069318A (ko) * 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 조절하는 화합물
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
DK2234966T3 (da) * 2007-12-18 2014-01-06 Sanofi Sa Azetidinderivater, fremstilling og terapeutisk anvendelse heraf
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
BRPI0902481B8 (pt) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61928B1 (en) † 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
JPH04360167A (ja) * 1991-06-06 1992-12-14 Mitsubishi Kasei Corp 近接帯電装置
FR2713225B1 (fr) † 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
JPH07209959A (ja) * 1994-01-24 1995-08-11 Ricoh Co Ltd 帯電装置
US5596106A (en) † 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
EP0969852A4 (en) * 1996-10-31 2004-05-06 Merck & Co Inc COMBINATION THERAPY OF AGENTS FOR THE TREATMENT OF DIABETES AND OBESITY
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US6207005B1 (en) * 1997-07-29 2001-03-27 Silicon Genesis Corporation Cluster tool apparatus using plasma immersion ion implantation
EP0920864A1 (en) † 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
IL141769A0 (en) † 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation

Also Published As

Publication number Publication date
EA200300441A1 (ru) 2003-08-28
AU9393601A (en) 2002-04-15
IL155236A0 (en) 2003-11-23
HUP0302044A2 (hu) 2003-11-28
EP1328269B2 (fr) 2008-07-30
JP4221221B2 (ja) 2009-02-12
MXPA03002845A (es) 2004-09-10
NZ524904A (en) 2004-11-26
ES2217191T5 (es) 2009-02-16
DK1328269T4 (da) 2008-11-24
ES2217191T3 (es) 2004-11-01
FR2814678A1 (fr) 2002-04-05
DE60103556T2 (de) 2005-06-30
ZA200303015B (en) 2004-02-26
PL362833A1 (en) 2004-11-02
SI1328269T2 (sl) 2008-12-31
DK1328269T5 (da) 2009-03-16
HRP20030249A2 (en) 2005-02-28
EA005924B1 (ru) 2005-08-25
CN100409845C (zh) 2008-08-13
AU2001293936B2 (en) 2007-01-25
NO20031521D0 (no) 2003-04-03
SI1328269T1 (en) 2004-10-31
CA2424934A1 (fr) 2002-04-11
EE200300121A (et) 2005-04-15
HUP0302044A3 (en) 2005-05-30
WO2002028346A3 (fr) 2002-08-29
DK1328269T3 (da) 2004-09-20
BR0114410A (pt) 2004-02-17
NO20031521L (no) 2003-04-24
PT1328269E (pt) 2004-08-31
DE60103556T3 (de) 2009-04-09
CN1473040A (zh) 2004-02-04
FR2814678B1 (fr) 2002-12-20
KR20030036885A (ko) 2003-05-09
EP1328269A2 (fr) 2003-07-23
ATE267595T1 (de) 2004-06-15
BG107739A (bg) 2004-01-30
SK4032003A3 (en) 2003-09-11
DE60103556D1 (de) 2004-07-01
EP1328269B1 (fr) 2004-05-26
JP2004512279A (ja) 2004-04-22
WO2002028346A2 (fr) 2002-04-11
TR200401264T4 (tr) 2004-07-21

Similar Documents

Publication Publication Date Title
AU9393601A (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
AU2001293936A1 (en) Association of the CB1 receptor antagonist and sibutramin, for treating obesity
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
AU3652102A (en) Compounds and their uses
HUP0401924A3 (en) Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them
MXPA02012891A (es) Composiciones farmaceuticas de agentes estrogenicos.
HUP0302578A3 (en) Isoindole-imide compounds, compositions containing them, and use thereof
UA83620C2 (ru) Замещенные бензоксазолы и их аналоги как эстрогенные агенты
HUP0402003A3 (en) Substituted 1,4-benzodiazepines, pharmaceutical compositions containing them and uses thereof
RS36904A (en) Polymorphous form or rimonabant,preparation method and pharmaceutical, compositions containing same
WO2002064125A3 (en) Use of a farnesoid x receptor antagonist for treating hyperlipidemia
BG104916A (en) Calcilytic compounds
HK1060558A1 (en) 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof.
BG105277A (en) Prevention of migraine recurrence
HUP0300928A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
MXPA03003892A (es) Antagonistas del receptor bombesin.
MXPA03004414A (es) Natagonistas del receptor bombesin.
MXPA04001878A (es) Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii.
DE60212130D1 (en) Carvedilolpolymorph
RS47804A (en) 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
ZA200204592B (en) Dual-release compositions of a cyclooxygenase-2-inhibitor.
IT1317742B1 (it) Composizioni a rilascio controllato di metamizolo e tramadolo.
GB0024703D0 (en) Corrective mixture producer system